List of Excipients in Branded Drug ATROPINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
MWI	ATROPINE	atropine sulfate	13985-606	BENZALKONIUM CHLORIDE
MWI	ATROPINE	atropine sulfate	13985-606	EDETATE DISODIUM
MWI	ATROPINE	atropine sulfate	13985-606	HYDROCHLORIC ACID
MWI	ATROPINE	atropine sulfate	13985-606	HYPROMELLOSE 2910
MWI	ATROPINE	atropine sulfate	13985-606	SODIUM HYDROXIDE
MWI	ATROPINE	atropine sulfate	13985-606	SODIUM PHOSPHATE, DIBASIC

Generic Drugs Containing ATROPINE

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	atropine sulfate	50090-7000	BENZALKONIUM CHLORIDE
A-S Medication Solutions	atropine sulfate	50090-7000	EDETATE DISODIUM
A-S Medication Solutions	atropine sulfate	50090-7000	HYDROCHLORIC ACID
A-S Medication Solutions	atropine sulfate	50090-7000	HYPROMELLOSE 2910
A-S Medication Solutions	atropine sulfate	50090-7000	SODIUM HYDROXIDE
A-S Medication Solutions	atropine sulfate	50090-7000	SODIUM PHOSPHATE, DIBASIC

What are the Most Frequently-Used Excipients in ATROPINE?

# Of NDCs	Excipient
5	BENZALKONIUM CHLORIDE
5	EDETATE DISODIUM
5	HYDROCHLORIC ACID
5	HYPROMELLOSE 2910
5	SODIUM HYDROXIDE
5	SODIUM PHOSPHATE, DIBASIC

# Atropine Excipient Strategy and Commercial Opportunities: Formulation, Regulatory, Patent and Market Analysis

Last updated: August 7, 2026

Atropine is a low-cost, off-patent active pharmaceutical ingredient with limited molecule-level exclusivity. Commercial value is concentrated in delivery systems, preservative-free ophthalmic products, pediatric low-dose formulations, emergency autoinjectors, stability improvements, and manufacturing controls. The strongest opportunities are differentiated products that solve dosing, tolerability, portability, or supply-chain problems rather than conventional atropine tablets or standard injectable generics.

What pharmaceutical products contain atropine?

Atropine is marketed primarily as atropine sulfate, the water-soluble salt used in injectable and ophthalmic products. Its main approved or established applications are emergency medicine, ophthalmology, anesthesia, and treatment of anticholinergic toxicity from organophosphate or carbamate exposure.

Product category	Typical strength or dose	Route	Main use	Commercial status
Atropine sulfate injection	0.1 mg/mL and 0.4 mg/mL presentations are common	Intravenous, intramuscular, intraosseous	Symptomatic bradycardia and emergency medicine	Generic and institutional market
Atropine sulfate injection for poisoning	1 mg/mL or autoinjector presentations	Intramuscular	Organophosphate or nerve-agent exposure	Government, military and emergency procurement
Atropine ophthalmic solution	0.5%, 1% and other strengths	Topical ocular	Cycloplegia, mydriasis and uveitis-related treatment	Branded and generic products
Low-dose atropine ophthalmic solution	Approximately 0.01% to 0.05%	Topical ocular	Myopia control, generally off-label in the United States	Compounded and specialty products
Atropine ophthalmic ointment	Commonly 1%	Topical ocular	Cycloplegia and ocular inflammation	Limited commercial availability
Combination or controlled-delivery products	Product-specific	Ocular or injectable	Reduced dosing frequency or improved tolerability	Emerging opportunity

Atropine sulfate is generally supplied as a crystalline, water-soluble material. The molecule has a long-established pharmacopoeial and regulatory history, reducing active-ingredient development risk but also limiting the ability to obtain broad composition-of-matter protection.[1,2]

What excipients are used in atropine formulations?

The excipient strategy depends on route, concentration, container, dose volume and intended shelf life. Injectable products require the narrowest excipient profile because parenteral tolerability, sterility and compatibility dominate formulation design.

Injectable atropine

A conventional atropine sulfate injection typically uses:

• Water for Injection as the vehicle
• A pH-adjusting agent, where required
• Sodium chloride or another tonicity adjuster in selected presentations
• Nitrogen or another headspace-control approach in some packaging configurations
• No antimicrobial preservative in single-dose emergency presentations

Atropine sulfate is sufficiently water-soluble to support simple aqueous injections. The commercial challenge is not solubilization. It is control of pH, oxidation, particulate formation, container compatibility and long-term potency.

A preservative-free single-dose presentation is generally preferable for intravenous and intraosseous use. Preservatives can create avoidable safety and compatibility concerns, especially in neonates, pediatric patients and high-acuity emergency settings.

Ophthalmic atropine solution

Ophthalmic solutions may contain:

• Purified water
• Boric acid and sodium borate or another buffer system
• Sodium chloride or another tonicity modifier
• Benzalkonium chloride in multidose preserved products
• Hypromellose or another viscosity modifier
• Disodium edetate as a chelating agent in selected formulations
• Hydrochloric acid or sodium hydroxide for pH adjustment

The excipient profile varies by manufacturer and strength. Benzalkonium chloride is commercially convenient because it supports multidose packaging, but chronic ocular exposure can aggravate epithelial toxicity, dry-eye symptoms and ocular-surface disease. This creates a clear opportunity for preservative-free unit-dose or multidose systems.

Low-dose atropine for myopia control

Low-dose atropine products create a more difficult formulation problem than conventional 0.5% or 1% ophthalmic solutions. A 0.01% solution contains only 0.1 mg/mL of atropine base equivalent, so small errors in dilution, filling, assay or delivered drop volume can materially affect dose uniformity.

Relevant formulation requirements include:

• Accurate low-concentration assay
• Uniformity across the entire bottle or cartridge
• Low adsorption to container and closure materials
• Protection from light and temperature excursions
• Low microbial risk during repeated use
• Minimal ocular-surface irritation
• Consistent drop size
• Suitability for pediatric use

Compounded low-dose atropine products can have variable beyond-use dating and packaging practices. A commercially manufactured product with validated stability, dose uniformity and child-resistant packaging could command a premium even without new active-ingredient patents.

Which excipient strategies offer the strongest commercial opportunities?

The most attractive strategies address a documented product weakness. Standard excipient substitution alone rarely creates durable value unless it enables a regulatory, clinical or packaging advantage.

1. Preservative-free ophthalmic atropine

A preservative-free atropine product could target children receiving repeated low-dose therapy, patients with ocular-surface disease and patients requiring frequent ophthalmic administration.

Potential presentations include:

• Single-use polymer ampoules
• Blow-fill-seal unit-dose containers
• Multidose bottles with a preservative-free valve system
• Airless pump dispensers
• Single-patient cartridges

The main commercial barriers are packaging cost, microbial-control validation and dose accuracy. A preservative-free multidose product has greater differentiation than a conventional unit-dose bottle because it can improve convenience while avoiding benzalkonium chloride.

2. Low-dose pediatric atropine with validated stability

A ready-to-use 0.01%, 0.025% or 0.05% atropine product could replace pharmacy-compounded preparations in myopia-control markets. Commercial positioning would depend on:

• Pediatric-appropriate bottle or cartridge design
• Accurate delivery of a small drop
• Stability at refrigerated and room temperatures
• Reliable expiration dating
• Low-cost distribution through ophthalmology and optometry channels
• Clear labeling for the intended market and jurisdiction

In the United States, low-dose atropine for myopia control has generally been used off-label rather than under a dedicated FDA approval. A sponsor seeking a labeled indication would need clinical and regulatory support for efficacy, safety, dose selection and pediatric use.[3,4]

3. Viscosity-controlled ophthalmic delivery

A modest increase in viscosity can reduce drainage through the nasolacrimal duct and improve ocular residence time. Hydroxypropyl methylcellulose, hydroxypropyl cellulose, carbomers or other ophthalmic polymers may be considered.

The tradeoff is significant. Higher viscosity can cause blurred vision, altered drop size, stringiness and reduced patient acceptance. A formulation patent would be more defensible if the sponsor demonstrates a specific combination of residence time, tolerability, dose uniformity and stability rather than merely adding a conventional thickener.

4. Sustained-release ocular delivery

Atropine has potential for depot or extended-release ocular systems because the treatment objective in myopia control may require long-term, repeated exposure. Possible platforms include:

• In situ gels
• Ocular inserts
• Biodegradable microspheres
• Drug-loaded contact lenses
• Punctal plugs
• Nanoparticle or liposomal carriers
• Hydrogel-based depot systems

The technical risk is higher than for an aqueous drop. Atropine can produce photophobia, blurred near vision and cycloplegia. A sustained-release system that cannot be rapidly discontinued may create a poor risk-benefit profile in children. Commercial development is more credible for a system that reduces peak exposure while preserving therapeutic effect.

5. Emergency autoinjector and combination delivery

Atropine autoinjectors are differentiated by dose, speed, ruggedness, shelf life and operational simplicity. The main customers are governments, military organizations, emergency responders, industrial employers and strategic stockpilers.

Excipient innovation is less important than:

• Chemical stability under temperature stress
• Compatibility with the injector
• Low extractables and leachables
• Reliable actuation after long storage
• Human-factors performance
• Dose delivery through clothing
• Compact packaging
• Shelf-life extension

A combination autoinjector containing atropine with an oxime such as pralidoxime can offer procurement value, but the device and regulatory strategy become substantially more complex. Atropine-only products may remain preferable where dosing must be titrated independently.

What patents protect atropine products?

Atropine itself is a legacy active ingredient, and broad composition-of-matter patent protection is not commercially relevant. The patent opportunity lies in secondary protection.

Potential patent categories include:

Patent category	Protectable subject matter	Commercial value
Formulation	Low-dose composition, buffer, polymer, preservative-free system or stability profile	Moderate to high if tied to clinical or manufacturing benefit
Container closure	Multidose preservative-free bottle, valve, cartridge or unit-dose package	Moderate
Device	Autoinjector mechanics, dose selection, safety interlock or packaging	High for government and emergency markets
Method of use	Myopia-control regimen, titration, combination therapy or disease-specific use	Variable and jurisdiction-dependent
Manufacturing	Sterile filling, low-dose dilution, crystallization, impurity control or container conditioning	Moderate
Controlled release	Ocular depot, insert, gel, contact lens or microparticle system	Potentially high, with greater development risk
Pediatric delivery	Drop-size control, child-resistant packaging or dosing system	Moderate

A patent portfolio focused only on “atropine plus a conventional buffer” is likely to face substantial validity and obviousness challenges. Stronger claims would require defined concentration ranges, excipient ratios, stability data, performance metrics or clinically meaningful outcomes.

What is the Orange Book status of atropine?

The FDA Orange Book records approved drug products and, for eligible listed drugs, patent and regulatory exclusivity information. Atropine products are generally mature products with generic competition and limited current market exclusivity at the active-ingredient level.[1]

Orange Book analysis must be conducted by specific product, dosage form, strength, NDA and manufacturer. A conclusion about “atropine” as a whole would be inaccurate because injectable atropine, ophthalmic atropine and autoinjector products can have different regulatory histories and listing structures.

For a differentiated sponsor, the relevant strategy is usually:

1. Obtain approval for a new formulation, delivery system or device.
2. Identify patents that claim the approved product or method of use.
3. Seek listing where FDA requirements are met.
4. Use regulatory exclusivity, if available, to supplement patent protection.
5. Monitor Paragraph IV certifications from generic applicants.

A new atropine formulation would not automatically receive the same regulatory treatment as a novel active ingredient. The pathway may involve a 505(b)(2) application where the sponsor relies partly on published literature or an existing reference product, or an abbreviated pathway if the product meets applicable generic requirements.[5]

When does atropine lose exclusivity?

The original atropine active ingredient has already lost practical exclusivity. The commercial question is whether a specific differentiated product has remaining patent or regulatory protection.

Protection type	Relevance to atropine	Strategic implication
Composition-of-matter patent	Generally expired or unavailable for the legacy active	No protection for standard atropine
Formulation patent	May protect a specific concentration, excipient system or stability profile	Useful if claims survive validity review
Device patent	May protect an autoinjector or preservative-free dispenser	Can create product-level barriers
Method-of-use patent	May cover a dosing regimen or indication	Enforcement depends on labeling and induced-use evidence
New-drug exclusivity	Product-specific and pathway-dependent	Could delay competing approvals
Pediatric exclusivity	Requires qualifying FDA action	Adds six months to eligible exclusivity periods
Orphan exclusivity	Relevant only to an approved orphan use	Indication-specific

For a conventional atropine injection or ophthalmic solution, generic entry risk is high. For a low-dose pediatric product, preservative-free multidose system or autoinjector, the relevant protection period would depend on the filing date and claim scope of the specific product patents.

How strong is the patent estate for atropine?

The legacy atropine patent estate is weak at the molecule level but potentially strong at the platform level.

Stronger patent positions

A sponsor can improve patent strength by claiming:

• Narrow but experimentally supported concentration ranges
• Defined pH and osmolality windows
• Specific preservative-free packaging systems
• Stability under accelerated and real-time conditions
• A measurable reduction in ocular-surface toxicity
• Improved dose uniformity for low-dose products
• Defined release kinetics in an ocular depot
• Device-specific delivery and safety features
• Clinical outcomes linked to a defined formulation

Weaker patent positions

Risk is higher for claims covering:

• Atropine with routine ophthalmic buffers
• Atropine with a standard viscosity modifier
• Broad “pharmaceutical composition” claims
• Conventional aqueous injection compositions
• Generic use of atropine for known indications
• Excipient substitutions without comparative performance data

Freedom-to-operate analysis should cover U.S., European, Chinese, Japanese and major commercial jurisdictions. The most relevant third-party rights may belong to platform companies with patents on ocular inserts, contact lenses, microparticles, airless packaging or preservative-free dispensing systems rather than to traditional atropine manufacturers.

Which companies are challenging or competing with atropine products?

Atropine competes across separate clinical and procurement markets.

Ophthalmic market

Competition includes:

• Generic atropine sulfate ophthalmic solution manufacturers
• Branded ophthalmic suppliers
• Compounding pharmacies supplying low-dose atropine
• Myopia-control companies developing novel low-dose or sustained-release products
• Alternative myopia-control treatments, including orthokeratology, multifocal contact lenses and other pharmacological approaches

The competitive gap is greatest in standardized, commercially manufactured low-dose atropine. That segment has more room for differentiation than the conventional 1% ophthalmic market.

Emergency market

Competition includes:

• Generic atropine injection manufacturers
• Autoinjector manufacturers
• Government-contracted medical suppliers
• Combination antidote developers
• International suppliers serving military and civil-defense procurement

Emergency markets are qualification-heavy. Procurement decisions depend on supply assurance, shelf life, device reliability and manufacturing capacity as much as on unit price.

What litigation and Paragraph IV risks affect atropine?

Standard atropine generics face limited litigation risk from the legacy active ingredient. Litigation risk increases when a sponsor commercializes a new delivery system or obtains patents covering:

• Preservative-free multidose packaging
• Low-dose myopia-control formulations
• Sustained-release ocular systems
• Autoinjector architecture
• Method-of-use regimens

A generic applicant could file a Paragraph IV certification against listed patents for an approved differentiated product. The patent holder would then face the standard statutory framework for filing an infringement action and potentially obtaining a 30-month stay of approval, subject to the specific regulatory record.[5]

For a low-dose atropine product marketed for an off-label use, method-of-use enforcement is more difficult than for a product with a dedicated approved indication. Label design and physician prescribing behavior become material to induced-infringement analysis.

What manufacturing and formulation barriers limit market entry?

Atropine is inexpensive, but reliable commercialization still requires specialized controls.

Low-dose manufacturing barriers

The main risks are dilution accuracy, blend uniformity, adsorption, assay sensitivity and filling precision. These risks increase sharply below 0.05% concentrations.

Sterile manufacturing barriers

Ophthalmic and injectable products require validated aseptic processing or terminal sterilization where feasible. Container closure integrity, particulate control and endotoxin limits are critical.

Packaging barriers

A preservative-free multidose product requires a validated microbial-barrier system. The package must preserve sterility after repeated actuation without creating unacceptable dose variability.

Supply-chain barriers

Atropine sulfate is widely available, but emergency products may require strategic inventories, dual sourcing and validated alternate suppliers. Government contracts may impose domestic manufacturing, surge capacity or minimum shelf-life requirements.

How does atropine compare with competing anticholinergic products?

Attribute	Atropine	Homatropine	Cyclopentolate	Tropicamide
Duration of ocular effect	Long	Intermediate to long	Intermediate	Short
Pediatric myopia-control interest	High	Low	Low	Low
Need for low-dose formulation	High	Limited	Limited	Limited
Emergency systemic use	High	Low	Low	Low
Preservative-free opportunity	High	Moderate	Moderate	Moderate
Commercial differentiation	Delivery and dose control	Formulation and tolerability	Faster onset and recovery	Convenience and shorter duration

Atropine has the broadest commercial opportunity because it spans emergency medicine and ophthalmology. Its long ocular duration creates both a therapeutic advantage and a tolerability problem. Formulation development should focus on controlling exposure rather than simply increasing residence time.

What FDA regulatory pathway is appropriate for a new atropine product?

The pathway depends on the product concept.

• A conventional injectable equivalent may qualify for an abbreviated application if it meets applicable sameness and bioequivalence requirements.
• A new ophthalmic strength, excipient system or delivery device may support a 505(b)(2) application.
• A novel sustained-release ocular system may require clinical studies, device characterization and a combination-product assessment.
• A dedicated myopia-control indication would require evidence supporting the intended pediatric population and dosing regimen.
• A new autoinjector may require drug-device combination-product review, human-factors testing and performance validation.

FDA labeling, inactive ingredients, container closure systems and manufacturing controls must be evaluated together. A new excipient is not required for commercial differentiation. A known excipient used in a novel, well-supported system may offer a faster development path.

What are the most attractive commercial opportunities for atropine?

The strongest opportunities rank as follows:

1. Preservative-free low-dose atropine for pediatric myopia control.
2. Ready-to-use, stability-validated atropine products replacing compounded preparations.
3. Preservative-free multidose ophthalmic delivery.
4. Long-shelf-life atropine autoinjectors for government and emergency procurement.
5. Low-dose drop-size-controlled systems for pediatric use.
6. Sustained-release ocular delivery with improved tolerability.
7. Dual-source or domestic-manufactured emergency atropine supply.
8. Specialty atropine products for ocular inflammation and perioperative use.

Revenue potential depends on market access rather than API cost. A conventional generic injection is a price-driven business with limited margins. A differentiated ophthalmic product can support higher pricing if it delivers validated stability, convenience, tolerability or regulatory certainty.

Key Takeaways

• Atropine is commercially mature and has no meaningful active-ingredient exclusivity.
• Excipient strategy should focus on preservative-free delivery, low-dose accuracy, stability and pediatric usability.
• The most credible opportunity is a regulated, ready-to-use low-dose ophthalmic product for myopia control.
• Sustained-release systems offer higher patent value but carry greater clinical and formulation risk.
• Autoinjector value depends more on device reliability, shelf life and procurement qualification than on excipient innovation.
• Conventional atropine products face high generic-entry risk.
• Strong secondary patents require specific formulation, packaging, release or clinical-performance data.
• FDA pathway selection will likely determine whether a new product competes on price or obtains differentiated market protection.

FAQs

Is atropine sulfate a new chemical entity?

No. Atropine sulfate is a long-established active pharmaceutical ingredient. Commercial protection must come from formulation, device, manufacturing or method-of-use claims.

Can benzalkonium chloride be removed from atropine eye drops?

Yes, but removal requires a validated preservative-free package or single-use presentation that maintains sterility throughout the labeled use period.

Is low-dose atropine for myopia control FDA approved in the United States?

Low-dose atropine has generally been used off-label for myopia control in the United States. A sponsor seeking a specific FDA-approved myopia indication would need an appropriate clinical and regulatory program.[3,4]

Does a new atropine excipient create patent protection?

Not automatically. Patent strength depends on whether the excipient system is novel, nonobvious, technically supported and linked to a measurable product or clinical advantage.

What is the best package for commercial low-dose atropine?

A preservative-free, child-resistant, dose-consistent multidose system offers the strongest balance of convenience and differentiation, provided microbial protection and drop uniformity are validated.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. United States Pharmacopeial Convention. (2024). USP-NF: Atropine sulfate and related monographs. https://www.usp.org/

3. U.S. Food and Drug Administration. (2023). Atropine sulfate ophthalmic solution prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

4. American Academy of Ophthalmology. (2023). Myopia and atropine treatment guidance. https://www.aao.org/

5. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-resources